Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia
- PMID: 39737360
- PMCID: PMC11682556
- DOI: 10.18502/ijm.v16i6.17244
Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia
Abstract
Background and objectives: Nosocomial pneumonia caused by multidrug-resistant gram-negative bacteria presents a significant challenge for healthcare systems, as there are limited effective treatments available. This systematic review and meta-analysis aim to investigate the outcomes of colistin plus meropenem combination therapy on nosocomial pneumonia.
Materials and methods: An exhaustive search of PubMed, Scopus, Web of Science (WOS), and Embase databases was conducted, resulting in the extraction of 5 studies for qualitative assessment and meta-analysis. The study sample included 991 patients admitted with nosocomial pneumonia. The outcomes evaluated were clinical improvement, microbiological response, mortality, Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation (APACHE II) score, Charlson Comorbidity Index (CCI), Clinical Pulmonary Infection Score (CPIS), C-reactive protein (CRP) levels, procalcitonin (PCT) levels, and intensive care unit (ICU) duration.
Results: The results demonstrated that colistin plus meropenem combination therapy significantly improved clinical outcomes (OR = 1.37, 95% CI = 1.04-1.81, p = 0.027), reduced SOFA scores (OR = -0.28, 95% CI = -0.44 to -0.11, p = 0.001), and increased CCI scores (OR = 0.16, 95% CI = 0.02-0.29, p = 0.021) compared to other medications. However, other evaluated parameters did not show significant differences.
Conclusion: This meta-analysis indicates that colistin-meropenem combination therapy is superior to other colistin-based treatments for nosocomial pneumonia in terms of clinical improvement, SOFA score reduction, and CCI score increase. Nevertheless, other variables assessed did not exhibit remarkable differences between the treatment regimens.
Keywords: Colistin; Meropenem; Multiple drug-resistance; Nosocomial infection; Pneumonia.
Copyright© 2024 The Authors. Published by Tehran University of Medical Sciences.
Figures



Similar articles
-
Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study.Sci Rep. 2022 May 7;12(1):7501. doi: 10.1038/s41598-022-11061-7. Sci Rep. 2022. PMID: 35525867 Free PMC article.
-
Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae.J Glob Antimicrob Resist. 2018 Dec;15:127-135. doi: 10.1016/j.jgar.2018.07.003. Epub 2018 Oct 11. J Glob Antimicrob Resist. 2018. PMID: 30010061 Clinical Trial.
-
Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis.Ann Intensive Care. 2024 Apr 25;14(1):66. doi: 10.1186/s13613-024-01291-5. Ann Intensive Care. 2024. PMID: 38662091 Free PMC article.
-
Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis.J Clin Med. 2022 Jun 6;11(11):3239. doi: 10.3390/jcm11113239. J Clin Med. 2022. PMID: 35683622 Free PMC article. Review.
-
Comparison of different colistin regimens for the treatment of pneumonia caused by multidrug-resistant microorganisms: a systematic review and meta-analysis.Eur Rev Med Pharmacol Sci. 2021 Aug;25(16):5275-5292. doi: 10.26355/eurrev_202108_26549. Eur Rev Med Pharmacol Sci. 2021. PMID: 34486704
References
-
- Tesini BL, Dumyati G. Health care-associated infections in older adults: epidemiology and prevention. Infect Dis Clin North Am 2023; 37: 65–86. - PubMed
-
- Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63(5): e61–e111. - PMC - PubMed
-
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268–281. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous